

Healthcare Provider

There may be times when you need to reduce your patient's dose because they have experienced an adverse reaction or are taking certain concomitant medications. The **IMBRUVICA® By Your Side** Dose Exchange Program is available to facilitate this dose reduction if you decide to adjust your patient's dose before they have finished their current pack of IMBRUVICA®. Your patient may qualify for the **IMBRUVICA® By Your Side** Dose Exchange Program if your patient meets each of the requirements in the Program Eligibility section below. Please complete this form, sign it, and fax it back to the **IMBRUVICA® By Your Side** Dose Exchange Program.

Please note that the **IMBRUVICA® By Your Side** Dose Exchange Program is facilitated by the **IMBRUVICA® By Your Side** Dose Exchange Program pharmacy and not by the specialty or in-office dispensing pharmacy to which the patient's previous prescription was submitted.

For ongoing refills, a new prescription will need to be submitted to the patient's existing specialty or in-office dispensing pharmacy.

Patient Prescription Information

NAME (First, MI, Last) _____ DOB (MM/DD/YYYY) _____

PHONE _____ ADDRESS _____

Dose Exchange Prescription (Current Strength)	New Strength	
Rx: <input type="checkbox"/> IMBRUVICA® (ibrutinib) 560 mg tablet	<input type="checkbox"/> IMBRUVICA® (ibrutinib) 420 mg tablet	DIRECTIONS: 1 pill taken PO once daily
<input type="checkbox"/> IMBRUVICA® (ibrutinib) 420 mg tablet	<input type="checkbox"/> IMBRUVICA® (ibrutinib) 280 mg tablet	QTY: _____ pills remaining to be exchanged (not to exceed 28 pills)
<input type="checkbox"/> IMBRUVICA® (ibrutinib) 280 mg tablet	<input type="checkbox"/> IMBRUVICA® (ibrutinib) 140 mg tablet	DIAGNOSIS CODE: _____
<input type="checkbox"/> IMBRUVICA® (ibrutinib) 140 mg tablet	<input type="checkbox"/> IMBRUVICA® (ibrutinib) 70 mg capsule	

Prescriber's Signature X _____ DATE _____

Prescriber Information

PRESCRIBER'S NAME (First, Last) _____ SPECIALTY _____

PRACTICE NAME _____ OFFICE CONTACT _____

STREET ADDRESS _____ CITY _____ STATE _____ ZIP _____

PHONE _____ FAX _____ NPI# _____

Program Eligibility

To be eligible for participation in the **IMBRUVICA® By Your Side** Dose Exchange Program, patients

1. Must have remaining pills from a current prescription for an FDA-approved indication for IMBRUVICA®.
2. Must return their remaining pills. Instructions for return will be provided with a pre-addressed envelope for the patient to return the unused quantity of previous strength.

Below are Required Terms and Conditions for the Program

- **IMBRUVICA® By Your Side** Dose Exchange Program is available to a given patient for up to two (2) separate dose reductions. The quantity to be exchanged should not exceed 28 pills per exchange.
- Neither Prescriber, Prescriber's institution, Pharmacy, Pharmacist, or any other person, including the patient, may seek payment or accept reimbursement from any patient, any third-party payer, including any state or federal entity or any private or other insurance plan, or from any other person or entity, for IMBRUVICA® supplied under this Program, regardless of whether the payer subsequently determines it will cover the product.
- With respect to product provided to Medicare Part D patients pursuant to the Program, Pharmacy must notify such patients' Part D plans that product is being provided to these patients outside the Part D benefit, and that no part of the costs of the drug provided as part of the Program shall be counted towards any Part D patient's out-of-pocket costs, and no claim will be filed with a Part D plan or by a Part D patient for such drug. As a condition of this Program, the applicable pharmacist will provide an appropriate notification to the patient's Part D plan. Notification will be provided as a payment-related use and disclosure pursuant to the Health Insurance Portability and Accountability Act and state privacy laws.
- Product provided pursuant to this Program may not be sold, traded or distributed for sale.
- In my medical judgment, the new strength of IMBRUVICA® is clinically appropriate for the patient named above and its use is consistent with the FDA-approved indication. This supply of IMBRUVICA® is specifically for the patient named above. Patient must be a resident of the United States or Puerto Rico.
- I have explained to my patient that he or she must return the unused drug according to the instructions provided by the **IMBRUVICA® By Your Side** Dose Exchange Program.

Prescriber: I certify that I understand and agree to comply with all of my obligations as they relate to the above referenced Program Eligibility and Terms and Conditions.

Prescriber's Signature X _____ DATE _____

Pharmacist: I certify that I understand and agree to comply with all of my obligations as they relate to the above referenced Program Eligibility and Terms and Conditions stated herein. In addition, I certify that I have read the required Program Eligibility and Terms and Conditions of this Program to the patient and received confirmation from the patient that he/she understands and will comply with the Terms and Conditions.

IMBRUVICA® By Your Side Pharmacist's Signature X _____ DATE _____

For assistance or additional information, call 888-YourSide (888-968-7743), Monday-Friday, 8:00 AM – 8:00 PM ET.

Please see Important Safety Information and full Indications on next page. Please see full Prescribing Information.

1. **IMBRUVICA® By Your Side** is a PharmacyClics, LLC, ("PCYC") and Janssen Biotech, Inc. sponsored program that provides personalized patient support ("By Your Side").
2. PCYC, its affiliates, collaborators and agents ("PCYC") will use your personal information, including your health information, collected through your enrollment and participation in "By Your Side" to: (1) provide you with support and communications for your prescribed product; and (2) perform research and analytics. For more information about PCYC's privacy practices or how to opt-out, visit <https://www.pharmacyclics.com/privacy-policy>.

INDICATIONS

IMBRUVICA® (ibrutinib) is a kinase inhibitor indicated for the treatment of adult patients with:

- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
- Waldenström's macroglobulinemia (WM).
- Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
- Mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

- Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA®. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA® in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA®, respectively.

The mechanism for the bleeding events is not well understood.

Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA® increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA® without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA®. Monitor for signs and symptoms of bleeding.

Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections: Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA® therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients who received IMBRUVICA® in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and *Pneumocystis jirovecii* pneumonia (PJP) have occurred in patients treated with IMBRUVICA®. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections.

Monitor and evaluate patients for fever and infections and treat appropriately.

Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8% and grade 3 or 4 anemia in 3%, based on laboratory measurements.

Monitor complete blood counts monthly.

Cardiac Arrhythmias and Cardiac Failure: Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA®. Grade 3 or greater ventricular tachyarrhythmias occurred in 0.2% of patients, Grade 3 or greater atrial fibrillation and atrial flutter occurred in 4%, and Grade 3 or greater cardiac failure occurred in 1% of 1,476 patients who received IMBRUVICA® in clinical trials. These events have occurred particularly in patients with cardiac risk factors, hypertension, acute infections, and a previous history of cardiac arrhythmias.

At baseline and then periodically, monitor patients clinically for cardiac arrhythmias and cardiac failure. Obtain an ECG for patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness, syncope, chest pain) or new onset dyspnea. Manage cardiac arrhythmias and cardiac failure appropriately, and if it persists, consider the risks and benefits of IMBRUVICA® treatment and follow dose modification guidelines.

Hypertension: Hypertension occurred in 19% of 1,476 patients who received IMBRUVICA® in clinical trials. Grade 3 or greater hypertension occurred in 8% of patients. Based on data from 1,124 of these patients, the median time to onset was 5.9 months (range, 0.03 to 24 months).

Monitor blood pressure in patients treated with IMBRUVICA® and initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA® as appropriate.

Second Primary Malignancies: Other malignancies (10%), including non-skin carcinomas (4%), occurred among the 1,476 patients who received IMBRUVICA® in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%).

Tumor Lysis Syndrome: Tumor lysis syndrome has been infrequently reported with IMBRUVICA®. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions.

Monitor patients closely and treat as appropriate.

Embryo-Fetal Toxicity: Based on findings in animals, IMBRUVICA® can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during the same time period.

ADVERSE REACTIONS

B-cell malignancies: The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%)*, diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%)*, rash (35.8%), anemia (35.0%)*, and bruising (32.0%).

The most common Grade ≥ 3 adverse reactions (≥5%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were neutropenia (20.7%)*, thrombocytopenia (13.6%)*, pneumonia (8.2%), and hypertension (8.0%).

Approximately 9% (CLL/SLL), 14% (MCL), 14% (WM) and 10% (MZL) of patients had a dose reduction due to adverse reactions. Approximately 4-10% (CLL/SLL), 9% (MCL), and 7% (WM [5%] and MZL [13%]) of patients discontinued due to adverse reactions.

cGVHD: The most common adverse reactions (≥20%) in patients with cGVHD were fatigue (57%), bruising (40%), diarrhea (36%), thrombocytopenia (33%)*, muscle spasms (29%), stomatitis (29%), nausea (26%), hemorrhage (26%), anemia (24%)*, and pneumonia (21%).

The most common Grade 3 or higher adverse reactions (≥5%) reported in patients with cGVHD were pneumonia (14%), fatigue (12%), diarrhea (10%), neutropenia (10%)*, sepsis (10%), hypokalemia (7%), headache (5%), musculoskeletal pain (5%), and pyrexia (5%).

Twenty-four percent of patients receiving IMBRUVICA® in the cGVHD trial discontinued treatment due to adverse reactions. Adverse reactions leading to dose reduction occurred in 26% of patients.

*Treatment-emergent decreases (all grades) were based on laboratory measurements.

DRUG INTERACTIONS

CYP3A Inhibitors: Co-administration of IMBRUVICA® with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations. Dose modifications of IMBRUVICA® may be recommended when used concomitantly with posaconazole, voriconazole, and moderate CYP3A inhibitors. Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA® if strong inhibitors are used short-term (e.g., for ≤ 7 days). See dose modification guidelines in USPI sections 2.3 and 7.1.

CYP3A Inducers: Avoid coadministration with strong CYP3A inducers.

SPECIFIC POPULATIONS

Hepatic Impairment (based on Child-Pugh criteria): Avoid use of IMBRUVICA® in patients with severe hepatic impairment. In patients with mild or moderate impairment, reduce recommended IMBRUVICA® dose and monitor more frequently for adverse reactions of IMBRUVICA®.

Please see full Prescribing Information.